Demant A/S : Q1 review – Hearing aids strong, Communication weaker than expected
>Hearing aids continued strong momentum - Demant’s Q1 2022 revenues of DKK 4,603m (+6.1% y-o-y) were 0%/-2% vs ODDO BHF/consensus. Organic growth of 6% was ahead of ODDO BHF’s 5% and the consensus’ expectations of 4.2%. Acquisitions contributed 100bp to growth and forex provided a tailwind of 300bp. Drivers of organic growth were a strong performance at hearing aids with 9% organic growth and revenues of DKK 2,351m. The Oticon More hearing aid platform expansion into ...William Demant Holding is a holding company. Through its subsidiaries, Co develops, manufactures and sells products and equipment designed to aid the hearing and communication of individuals. Co. focuses on four areas: Hearing Devices, Diagnostic Instruments, Hearing Implants and Personal Communication. Co.'s hearing devices include Oticon, Bernafon, Sonic, Phonic Ear, and FrontRow. Co.'s Hearing implant consist of Oticon Medical. Co.'s diagnostic instruments include Maico, Interacoustics, Amplivox, Grason-Stadler, MedRx, and Micromedical. Co.'s personal communication consists of Sennheiser Communications.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.